MNKD Stock Summary and Trading Ideas (Mannkind | NASDAQ:MNKD)

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Mannkind trades on the NASDAQ stock market under the symbol MNKD.

As of September 24, 2026, MNKD stock price declined to $3.27 with 693,010 million shares trading.

MNKD has a beta of 2.74, meaning it tends to be more sensitive to market movements. MNKD has a correlation of 0.18 to the broad based SPY ETF.

MNKD has a market cap of $1.05 billion. This is considered a Small Cap stock.

Last quarter Mannkind reported $109 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $798,600 and missed earnings estimates by -$.02.

In the last 3 years, MNKD traded as high as $7.63 and as low as $2.23.

The top ETF exchange traded funds that MNKD belongs to (by Net Assets): VTI, XBI, VXF, VTWO, SCHA.

MNKD has underperformed the market in the last year with a price return of -38.9% while the SPY ETF gained +16.4%. MNKD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.8% and -17.0%, respectively, while the SPY returned +4.4% and +0.5%, respectively.

MNKD support price is $3.23 and resistance is $3.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNKD shares will trade within this expected range on the day.